Nama's AI scorecard currently rates IQVIA Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is IQV's P/E ratio?

IQVIA trades at a trailing price-to-earnings ratio of 21.2.

When does IQV report earnings?

IQVIA's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $3.58.

What is the IQV price target?

The median analyst price target from 18 analysts is $310.00, with a range of $268.00 – $346.00.

Is IQV Shariah compliant?

Nama's AAOIFI-style screen reads IQVIA as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

IQVIA (IQV)

Healthcare · Diagnostics Research · NYSE

S&P 500

IQVIA (IQV) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $44.80B, a trailing price-to-earnings ratio of 21.2 and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 5.9% and free cash flow per share grew 2.6%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 5.2/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +22.4% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-4.8%

How far the last close sits under the highest price of the past five years.

Market cap	$44.80B
Trailing P/E	21.2
Price / book	6.7
Price / sales	2.6
FCF yield	4.3%
Dividend yield	—
Gross margin	33.1%
Operating margin	13.8%
Net margin	8.1%
Revenue growth (YoY)	+5.9%
Revenue growth (3-yr annual)	+4.2%
EPS growth (YoY)	+7.1%
FCF/share growth (YoY)	+2.6%
Beta	1.2
Exchange	NYSE
Sector	Healthcare
Industry	Diagnostics Research

IQV earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $3.58). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$3.34	$3.28	+1.8%	$4.43B
Q2 2026	Jul 28, 2026	$3.15	$3.03	+4.0%	$4.37B
Q1 2026	May 5, 2026	$2.90	$2.82	+2.8%	$4.15B
Q4 2025	Feb 5, 2026	$3.42	$3.40	+0.6%	$4.36B

IQV analyst price target

Median target $310.00 from 18 analysts, ranging $268.00 – $346.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2
ILMN	Illumina	$32.23B	40.6

Explore live IQV data on Nama Insights →

Recent Congressional trades

IQVIA trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Kevin Hern	House	Sell	$15,001 - $50,000	Sep 25, 2026
Kevin Hern	House	Sell	$1,001 - $15,000	Sep 25, 2026
Kevin Hern	House	Sell	$1,001 - $15,000	Sep 25, 2026
Kevin Hern	House	Sell	$50,001 - $100,000	Apr 3, 2026
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 31, 2025
Rob Bresnahan	House	Buy	$15,001 - $50,000	May 8, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Mar 27, 2025
John F Reed	Senate	Sell	$1,001 - $15,000	—
John F Reed	Senate	Sell	$1,001 - $15,000	—
John F Reed	Senate	Sell	$1,001 - $15,000	—

IQV FAQ

Is IQV a buy?: Nama's AI scorecard currently rates IQVIA Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is IQV's P/E ratio?: IQVIA trades at a trailing price-to-earnings ratio of 21.2.
When does IQV report earnings?: IQVIA's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $3.58.
What is the IQV price target?: The median analyst price target from 18 analysts is $310.00, with a range of $268.00 – $346.00.
Is IQV Shariah compliant?: Nama's AAOIFI-style screen reads IQVIA as Not Shariah Compliant. At least one of the three ratios or the industry test failed.